When Pfizer bought Seagen for $43 billion, it wasn't just buying a company - it was buying precision.
Seagen's antibody-drug conjugates (ADCs) proved that if you can guide chemotherapy directly to the tumor, you can make chemo powerful again.
Now, a new player looks to take that idea further.
Its breakthrough technology acts as a laser-guided system inside the cell, ensuring that once the drug finds the tumor, the toxic payload is delivered exactly where it's needed - not throughout the body.
Early data suggest higher potency at lower doses - a combination that could make ADCs not only stronger, but safer.
And here's the real kicker: this isn't a single-drug story.
The same platform can potentially plug into hundreds of existing therapies - from ADCs to vaccines to radiotherapies - upgrading how modern medicine delivers its payloads.
Seagen proved precision pays.
This next generation aims to make it universal.
Discover the breakthrough reshaping oncology
